糖尿病病中的Sirtuin 3:机制和药理疗法
Yinfeng Chen1, Ying Wang2, Dongrong Yu1
1Department of Nephrology, TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
Renal failure
|August 19, 2025
概括
赛尔图因3 (SIRT3) 通过改善线粒体功能和减少疾病进展,在治疗糖尿病病 (DKD) 中表现有前途. 激活SIRT3可能为糖尿病脏并发症提供新的治疗策略.
科学领域:
- 线粒体生物学 线粒体生物学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病病 (DKD) 是糖尿病的严重并发症,需要改进治疗方法.
- 赛尔图因3 (SIRT3) 是线粒体脱乙酶,调节关键的细胞功能.
- 新出现的证据表明SIRT3是DKD的潜在治疗点.
研究的目的:
- 审查SIRT3在线粒体功能中的作用,与DKD相关.
- 总结一下SIRT3对DKD进展的保护机制.
- 探索SIRT3激活剂在脏疾病中的治疗潜力.
主要方法:
- 文献综述侧重于SIRT3对线粒体生物发生,自,动态,氧化应激和DKD中的能量代谢的影响.
- 对研究SIRT3对细胞过程 (如氧化应激,炎症,细胞死亡和新陈代谢) 的影响进行分析.
- 对脏疾病SIRT3激活剂的现有研究进行分类.
主要成果:
- 在维护线粒体平衡中,SIRT3起着至关重要的作用.
- 通过抑制氧化应激和炎症,SIRT3激活可以缓解DKD.
- SIRT3调节细胞死亡途径和能量代谢,从而延缓DKD的进展.
结论:
- SIRT3是线粒体功能的关键调节者,为糖尿病病提供了有前途的治疗标.
- 准SIRT3可能为管理和治疗DKD提供一种新的策略.
- 对于脏疾病的应用,SIRT3激活剂的进一步临床验证是必要的.
更多相关视频
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
279
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
545
相关概念视频
01:28Chronic Kidney Disease III: Interprofessional Care
78
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
78
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
01:25Chronic Kidney Disease I: Introduction
67
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
67
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291